Revolution Medicines (FRA:42Z) LT-Debt-to-Total-Asset: 0.06 (As of Mar. 2026)


FRA:42Z Revolution Medicines Inc FRA:42Z
30 GF Score
Price €167.00
GF Value €0.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Revolution Medicines LT-Debt-to-Total-Asset?

Revolution Medicines FRA:42Z -0.92% 30 LT-Debt-to-Total-Asset is 0.06 as of Mar. 2026. GuruFocus rates FRA:42Z with a GF Score™ of 30/100 and a GF Value™ of €0.41 (Significantly Overvalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Revolution Medicines's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.06.

Revolution Medicines's long-term debt to total assets ratio increased from Mar. 2025 (0.05) to Mar. 2026 (0.06). It may suggest that Revolution Medicines is progressively becoming more dependent on debt to grow their business.

Revolution Medicines  (FRA:42Z) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Revolution Medicines LT-Debt-to-Total-Asset Related Terms

Revolution Medicines LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Revolution Medicines's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revolution Medicines LT-Debt-to-Total-Asset Chart

Revolution Medicines Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only 0.08 0.07 0.04 0.05 0.06

Revolution Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.06 0.06 0.06
FRA:42Z
30GF Score
Revolution Medicines Inc FRA:42Z
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Revolution Medicines LT-Debt-to-Total-Asset Calculation

Revolution Medicines's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=121.468/2010.75
=

Revolution Medicines's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=121.116/1949.483
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.06 mean?
Revolution Medicines (FRA:42Z) has a LT-Debt-to-Total-Asset of 0.06 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Revolution Medicines and its competitors.
Is Revolution Medicines' LT-Debt-to-Total-Asset too high?
Revolution Medicines' current LT-Debt-to-Total-Asset is 0.06. Overall, Revolution Medicines has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Revolution Medicines' LT-Debt-to-Total-Asset compare to ALNY and ONC?
Revolution Medicines' LT-Debt-to-Total-Asset of 0.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Revolution Medicines and its competitors. Revolution Medicines's current LT-Debt-to-Total-Asset is 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revolution Medicines stock overvalued right now?
Based on GuruFocus' analysis, Revolution Medicines (FRA:42Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.41, compared to a current price of €167.00 — trading 40631.7% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.06. Revolution Medicines' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Revolution Medicines (FRA:42Z), the current LT-Debt-to-Total-Asset is 0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Revolution Medicines (FRA:42Z) Overvalued in 2026?

Based on GuruFocus' analysis, Revolution Medicines stock appears to be overvalued. The current stock price of €167.00 is trading 40631.7% above its estimated GF Value™ of €0.41. GuruFocus considers Revolution Medicines to be Significantly Overvalued.

Key valuation signals for FRA:42Z:

  • LT-Debt-to-Total-Asset: 0.06
  • GF Value™: €0.41 vs. price of €167.00 (40631.7% above fair value)
  • GF Score™: 30/100 with 4 warning signs

No single metric tells the full story. See the FRA:42Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Revolution Medicines Business Description

Address 700 Saginaw Drive, Redwood City, CA, USA, 94063
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
30GF Score

Get the complete analysis for FRA:42Z

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€167.00
Price
€0.41
GF Value